Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-585: Pembrolizumab plus chemotherapy as neoadjuvant/adjuvant therapy in gastric and gastroesophageal junction adenocarcinoma
jRCT2080223730Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Merck & Co. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223730.